胰腺癌（PC）是世界上最致命的癌症之一，生存率低且预后差。 PC 的治疗前景充满障碍，包括耐药性、缺乏有效的靶向治疗和免疫抑制肿瘤微环境 (TME)。 PC 对现有免疫疗法的耐药性凸显了对创新方法的需求，而 TME 正在成为一个有前途的治疗靶点。最近在了解巨噬细胞的作用方面取得了进展，这凸显了它们对肿瘤发生和进展的重大影响。巨噬细胞有两种重要类型：M1 和 M2，它们在 TME 中发挥着关键作用。包括消除肿瘤相关巨噬细胞 (TAM)、重新编程 TAM 以促进抗肿瘤活性以及靶向巨噬细胞招募在内的治疗策略可以带来有希望的结果。针对巨噬细胞相关通路可能为调节免疫反应、抑制血管生成和克服 PC 治疗中的化疗耐药性提供新策略。© 2024。作者。

Pancreatic cancer (PC) is one of the deadliest cancers worldwide with low survival rates and poor outcomes. The treatment landscape for PC is fraught with obstacles, including drug resistance, lack of effective targeted therapies and the immunosuppressive tumor microenvironment (TME). The resistance of PC to existing immunotherapies highlights the need for innovative approaches, with the TME emerging as a promising therapeutic target. The recent advancements in understanding the role of macrophages, this context highlight their significant impact on tumor development and progression. There are two important types of macrophages: M1 and M2, which play critical roles in the TME. Therapeutics strategies including, depletion of tumor-associated macrophages (TAMs), reprogramming TAMs to promote anti-tumor activity, and targeting macrophage recruitment can lead to promising outcomes. Targeting macrophage-related pathways may offer novel strategies for modulating immune responses, inhibiting angiogenesis, and overcoming resistance to chemotherapy in PC treatment.© 2024. The Author(s).